Materials and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Intrathecal Drug Delivery (ITDD) systems for cancer pain.F1000Res. 2013; 2: 96https://doi.org/10.12688/f1000research.2-96.v4
Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17:354–372 [discussion: 372]. https://doi.org/10.1111/ner.12146
- Intrathecal drug delivery for pain: a clinical guide and future directions.Pain Manag. 2015; 5: 175-183
- Choice of spinal cord stimulation versus targeted drug delivery in the management of chronic pain: a predictive formula for outcomes.Reg Anesth Pain Med. 2020; 45: 131-136
- Prognosis and prognostic research: validating a prognostic model.BMJ. 2009; 338: b605
- Predicting the response of high frequency spinal cord stimulation in patients with failed back surgery syndrome: a retrospective study with machine learning techniques.J Clin Med. 2020; 9: 4131
- A comprehensive algorithm for management of neuropathic pain.Pain Med. 2019; 20: S2-S12
- Public regulatory databases as a source of insight for neuromodulation devices stimulation parameters.Neuromodulation. 2018; 21: 117-125
- Multicenter retrospective study of neurostimulation with exit of therapy by explant.Neuromodulation. 2017; 20: 543-552
- Therapy-related explants after spinal cord stimulation: results of an international retrospective chart review study.Neuromodulation. 2017; 20: 642-649
- Explant rates of electrical neuromodulation devices in 1177 patients in a single center over an 11-year period.Reg Anesth Pain Med. 2020; 45: 883-890
Wang VC, Bounkousohn V, Fields K, Bernstein C, Paicius RM, Gilligan C. Explantation rates of high frequency spinal cord stimulation in two outpatient clinics. Neuromodulation. 2021;24:507–511. Published correction appears in Neuromodulation. 2021;24:1503.
- Predictors of reduced opioid use ith spinal cord stimulation in patients ith chronic opioid use.Neuromodulation. 2020; 23: 126-132
- Explantation rates and healthcare resource utilization in spinal cord stimulation.Neuromodulation. 2017; 20: 331-339
- The economic costs of pain in the United States.J Pain. 2012; 13: 715-724
- Long-term consequences of chronic pain: mounting evidence for pain as a neurological disease and parallels with other chronic disease states.Pain Med. 2011; 12: 996-1004
- Economic burden of back and neck pain: effect of a neuropathic component.Popul Health Manag. 2014; 17: 224-232
Publication stageIn Press Corrected Proof
Source(s) of financial support: The study was internally funded by Evidence-Based Pain Management Research at the Cleveland Clinic, Cleveland, Ohio, USA. Medtronic Neurologic provided access to the registry, and no funds were received.
Conflict of Interest: Nagy Mekhail served as the Medical Monitor for DRG stimulation “Accurate study”; closed-loop SCS “Evoke study”; HF-10 for PDN “Senza-PDN study”; Mild for LSS “Motion study”; ViaDisc-NP Pilot study for Discogenic pain”; and Restore Study for multifidus muscle dysfunction. Nagy Mekhail is also a consultant for Boston Scientific and Relievant Medsystems Inc. He has received research support from Mesoblast, Avanos, and Neuros Medical. The remaining authors reported no conflict of interest.